Iridex (NASDAQ:IRIX) Stock

Iridex

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Federal Reserve

Intraday Update

Markets

Trading Ideas

CLLS

IRIX

PATI

PAYC

TGTX

U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision.

The Dow traded up 0.40% to 33,185.41 while the NASDAQ rose 0.92% to 12,969.54. The S&amp;P 500 also rose, gaining, 0.67% to 4,221.94.

Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged

Movers

ALDX

ASTE

BALY

BGFV

CHEF

CNDT

CWBR

DTCK

Euda Health Holdings Limited - Ordinary Shares

EUDA

EXTR

FTDR

GDEV

GNRC

GOOS

GRMN

GTHX

Kintara Therapeutics, Inc. - Common Stock

KTRA

LIFW

LUMN

MNPR

MOTS

Merrill Lynch & Strategic Return Notes for Select 10 Index

MTCH

NMRK

PCTY

PIXY

PSTV

PUYI

SIEN

SITE

SLAB

SPWR

SYNA

TMPO

TNXP

TRTX

YUMC

ZVSA

Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.

The Dow traded up 0.55% to 33,233.33 while the NASDAQ rose 0.87% to 12,962.92. The S&amp;P 500 also rose, gaining, 0.74% to 4,224.85.

Nasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares Plunge

IRIDEX Corp

Iridex Corporation Says Q4 Revenues Will Bew Between $12.6M-$12.7M; FY24 Revenues Will Be Between  $48.6M-$48.7M

Biotech

General

Iridex Publishes Peer-Reviewed Study In Ophthalmology Therapy; Highlights Safety And Efficacy Of MicroPulse Transscleral Laser Therapy In Managing Both Primary And Secondary Glaucoma Over Five Years.

Health Care

Iridex Confirms That Local Coverage Determination L37531, Relating To Micro-Invasive Glaucoma Surgery Was Adopted As Scheduled And wll Be Effective For Services Performed After Nov. 17

WIIM

IRIDEX shares are trading higher. The company reported Q3 financial results.

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $11.58 million which missed the analyst consensus estimate of $12.50 million by 7.35 percent. This is a 9.88 percent decrease over sales of $12.85 million the same period last year.

Earnings Misses

Iridex Q3 EPS $(0.12) Misses $(0.09) Estimate, Sales $11.58M Miss $12.50M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-12. Here's what investors need to know before the announcement.
Analysts estimate that Iridex will report an earnings per share (EPS) of $-0.09. 
Iridex bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
Last quarter the company missed EPS by $0.04, which was followed by a 0.53% drop in the share price the next day.
Here's a look at Iridex's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.12</td>
<td>-0.05</td>
<td>-0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.16</td>
<td>-0.21</td>
<td>-0.18</td>
<td>-0.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-14.000000000000002%</td>
<td>18.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731341093_0.png" alt="eps graph" />
<h3>Market Performance of Iridex's Stock</h3>
Shares of Iridex were trading at $1.39 as of November 08. Over the last 52-week period, shares are down 27.37%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/IRIX/earnings">To track all earnings releases for Iridex visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Iridex's Upcoming Earnings

Management

Iridex Appoints Patrick Mercer As CEO

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 5.88 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $12.631 million which missed the analyst consensus estimate of $12.800 million by 1.32 percent. This is a 1.74 percent decrease over sales of $12.855 million the same period last year.

Iridex Q2 2024 GAAP EPS $(0.16) Misses $(0.11) Estimate, Sales $12.631M Miss $12.800M Estimate

Stifel analyst Thomas Stephan maintains Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) with a Hold and maintains $2 price target.

Price Target

Analyst Ratings

Stifel Maintains Hold on Iridex, Maintains $2 Price Target

IRIDEX shares are trading lower after the company reported worse-than-expected Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock rose 13.02% to $2.95. The market value of their outstanding shares is at $141.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 7.55% to $11.25. The company's market cap stands at $204.5 million. As per the news, the Q1 earnings report came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 6.74% to $0.93. The market value of their outstanding shares is at $12.4 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares rose 6.08% to $2.44. The market value of their outstanding shares is at $2.1 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock rose 5.81% to $0.06. The market value of their outstanding shares is at $7.1 million. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) stock fell 15.9% to $1.11 during Tuesday's after-market session. The market value of their outstanding shares is at $42.3 million. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock declined by 12.86% to $2.17. The company's market cap stands at $6.4 million. The company's, Q1 earnings came out today. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) shares decreased by 12.0% to $2.71. The company's market cap stands at $44.0 million. As per the press release, Q1 earnings came out today. </li>
<li>Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) stock fell 7.66% to $66.0. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q4 earnings came out today. </li>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) shares decreased by 7.32% to $0.41. The market value of their outstanding shares is at $32.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.77% to $1.47. The market value of their outstanding shares is at $50.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKLI

ARQT

BBLG

BCAB

BOLT

OCEA

OPRX

SINT

VVOS

12 Health Care Stocks Moving In Tuesday's After-Market Session

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.12) by 75 percent. This is a 61.54 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $11.76 million which missed the analyst consensus estimate of $12.00 million by 1.99 percent. This is a 14.19 percent decrease over sales of $13.71 million the same period last year.

Iridex Q1 2024 GAAP EPS $(0.21) Misses $(0.12) Estimate, Sales $11.76M Miss $12.00M Estimate

<h3>Gainers</h3>
<ul>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares increased by 73.2% to $1.1 during Thursday's after-market session. The company's market cap stands at $39.3 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares increased by 37.85% to $0.08. The market value of their outstanding shares is at $8.2 million. </li>
<li>Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) stock rose 12.19% to $0.55. The company's market cap stands at $54.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares moved upwards by 9.36% to $1.2. The company's market cap stands at $33.0 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) stock rose 8.73% to $1.12. The market value of their outstanding shares is at $19.0 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares increased by 8.62% to $17.12. The company's market cap stands at $1.2 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock fell 12.6% to $4.22 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million. As per the news, the Q4 earnings report came out today. </li>
<li>Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) stock declined by 12.31% to $0.57. The market value of their outstanding shares is at $92.3 million. </li>
<li>Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) stock decreased by 11.37% to $7.72. The company's market cap stands at $425.2 million. The company's, Q4 earnings came out today. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 9.27% to $1.47. The market value of their outstanding shares is at $6.2 million. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock fell 8.89% to $0.41. The company's market cap stands at $18.8 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock decreased by 8.28% to $2.77. The company's market cap stands at $45.0 million. As per the news, the Q4 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

DARE

PHGE

PLSE

RNAC

SBFM

TLPH

ZNTL

12 Health Care Stocks Moving In Thursday's After-Market Session

IRIDEX shares are trading higher. The company reported Q4 financial results.

<h3>Gainers</h3>
<ul>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares moved upwards by 7.36% to $0.78. The company's market cap stands at $42.8 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares moved upwards by 6.66% to $0.32. The company's market cap stands at $10.9 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares rose 6.44% to $7.75. The market value of their outstanding shares is at $5.8 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares increased by 6.38% to $0.5. The market value of their outstanding shares is at $4.6 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock increased by 5.52% to $2.65. The company's market cap stands at $43.0 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) stock decreased by 22.9% to $0.29 during Tuesday's after-market session. The company's market cap stands at $23.0 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock fell 11.34% to $1.02. The company's market cap stands at $15.0 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) shares decreased by 9.84% to $1.1. The market value of their outstanding shares is at $40.2 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares decreased by 7.21% to $3.6. The market value of their outstanding shares is at $4.2 million. </li>
<li>United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) shares declined by 7.21% to $230.0. The company's market cap stands at $10.8 billion. </li>
<li>ProSomnus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSA#NASDAQ">OSA</a>) stock decreased by 6.46% to $0.58. The market value of their outstanding shares is at $10.0 million. As per the press release, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Iridex

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga